Table 1

Patient characteristics

Tofacitinib 5 mg two times per dayTofacitinib 10 mg two times per dayTotal
Number of patients (n)151530
Disease duration (years), mean±SD (range)6.3±4.7 (1–15)7.1±4.9 (2–21)7.7±5.0 (1–21)
Age (years), mean±SD (range)52.3±11.4 (27–69)53.3±8.8 (34–69)52.8±10.0 (27–69)
Female sex, n (%)14 (93)13 (87)27 (90)
DAS28 (baseline), mean±SD4.80±0.695.29±0.795.05±0.77
RF positivity, n (%)12 (80)12 (80)24 (80)
ACPA positivity, n (%)13 (87)11 (73)24 (80)
Smoking (current) (n)437
Patients with comorbidity (n)
 Cardiovascular disease336
 Diabetes mellitus112
 Previous malignancy202
Concomitant use of csDMARDs (n)121123
 MTX +sulfasalazine101
 Leflunomide +sulfasalazine011
 Concomitant use of corticosteroids (n)4610
  • ACPA, anticitrullinated protein antibody; csDMARD, conventional synthetic disease-modifying antirheumatic drug; DAS28, 28-Joint Disease Activity Score; MTX, methotrexate; RF, rheumatoid factor.